Phenylbutazone possesses non-hormonal, anti-inflammatory activity of value in the management of musculoskeletal conditions in dogs and horses such as the arthritides, including osteoarthritis, and as an aid in the relief of inflammation associated with intervertebral disc syndrome in dogs.

**INDICATIONS**

Phenylbutazone possesses non-hormonal, anti-inflammatory activity of value in the management of musculoskeletal conditions in dogs and horses such as the arthritides, including osteoarthritis, and as an aid in the relief of inflammation associated with intervertebral disc syndrome in dogs.

**BENEFITS**

- **Rapid onset of activity:** usually provides relief within 24 hours
- **Proven:** safe and effective
- **Versatile:** treats inflammatory conditions in both dogs and horses
- **Safe:** approved by FDA

**PACKAGING**

<table>
<thead>
<tr>
<th>LIST NO.</th>
<th>UNIT PACKAGE</th>
<th>CASE SIZE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1BUT001</td>
<td>1 g x 100 ct</td>
<td>12</td>
</tr>
</tbody>
</table>

**WARNING**

Phenylbutazone should not be administered to meat, egg or milk producing animals because the status of residues of drug remaining in edible tissues has not been determined.

See reverse side for Administration and Dosage.
**INDICATIONS:**
Phenylbutazone possesses non-hormonal, anti-inflammatory activity of value in the management of musculoskeletal conditions in dogs and horses such as the arthritides, including osteoarthritis, and as an aid in the relief of inflammation associated with intervertebral disc syndrome in dogs.

**CONTRAINDICATIONS:**
Phenylbutazone should not be administered to animals with serious hepatic, renal or cardiac pathology, or those with a history of blood dyscrasia.

**WARNING:**
PHENYLBUTAZONE SHOULD NOT BE ADMINISTERED TO MEAT, EGG OR MILK PRODUCING ANIMALS BECAUSE THE STATUS OF RESIDUES OF DRUG REMAINING IN EDIBLE TISSUES HAS NOT BEEN DETERMINED.

**HAZARDS AND PRECAUTIONS:**
1. Use with caution in animals with a history of drug allergy.
2. Stop medication at the first sign of gastrointestinal upset, jaundice or blood dyscrasia. Authenticated cases of agranulocytosis associated with phenylbutazone have occurred in man. Phenybutazone induced blood dyscrasias have been reported in dogs. Thrombocytopenia and leukopenia are early manifestations followed by nonregenerative anemia. The occurrence of this reaction is not dose dependent and is unpredictable. To guard against this possibility, conduct routine blood counts at not more than 7 day intervals during the early course of therapy and at intervals of not more than 14 days throughout the course of therapy. Any significant fall in the total white count, relative decrease in granulocytes or black or tarry stools should be regarded as a signal for immediate cessation of therapy and institution of appropriate treatment.
3. When treating inflammatory conditions associated with infection, specific anti-infective therapy is required.
4. Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days of therapy, re-evaluate diagnosis and therapeutic regimen.

**DOSAGE - DOGS:**
**ORALLY**
20 mg per pound body weight (100 mg/5 lbs.) daily in 3 divided doses, not to exceed 800 mg daily regardless of body weight.

**DOSAGE - HORSES:**
**ORALLY**
1-2 grams per 500 lbs. body weight, not to exceed 4 grams daily.

**ADMINISTRATION:**
1. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing the desired clinical response.
2. In many cases tablets may be crushed and given with feed. Reduce the dosage as symptoms regress. In some cases treatment may be given only when symptoms appear with no need for continuous medication.
3. In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals.
4. Many chronic conditions will respond to phenylbutazone therapy but discontinuance of treatment may result in the recurrence of symptoms.

**STORAGE:**
Store at controlled room temperature, 20°C - 25°C (68°F - 77°F).

**HOW SUPPLIED:**
BUTATRON® (Phenylbutazone Tablets, USP) are supplied in the following tablet concentrations and package sizes:

- 1 gram tablets .................................................Bottles of 100 tablets

To obtain an MSDS or for assistance contact Bimeda, Inc. at 1-888-524-6332.

Manufactured by:
Bimeda, Inc.
Le Sueur, MN 56058
8BUT001